EUVIMED · CrossrefJournal
HemaSphere
ISSN 2572-9241 · Wiley
Latest articles
Chimeric antigen receptor T‐cell therapy as a cure for large B‐cell lymphoma
Emergency hematopoiesis in sepsis: A pathway to myeloid clonal expansion
Improved multistate survival in younger AML patients over time
Management of advanced mycosis fungoides and Sézary Syndrome: International Recommendations for systemic treatments and allogeneic hematopoietic cell transplantation from the European Hematology Association, the EORTC Cutaneous Lymphoma Tumours Group, the International Society for Cutaneous Lymphoma, and the Lymphoma Working Party of the EBMT
How we treat venous thromboembolism in pregnancy in a resource‐limited setting
Sustained disease remission with reduced‐intensity allogeneic hematopoietic cell transplant for VEXAS syndrome
Low tumor burden follicular lymphoma: The state of the art
Infections and their determinants in patients with non‐Hodgkin lymphoma receiving bispecific T‐cell antibodies: Results from an international multicenter cohort study
Differential recovery of macrophage iron deficiency by oral iron formulations determines inflammation and autocrine hepcidin production in iron‐deficiency anemia
Impact of venetoclax‐based therapies on CLL‐associated autoimmune cytopenias: A retrospective study conducted by ERIC
Modulation of the RNA‐sensing RIG/MAVS pathway bypasses resistance to hypomethylating agents in acute myeloid leukemia
Maladaptive DNA damage responses impair CD8 T‐cell fitness after allogeneic stem cell transplantation
Lineage switch in childhood leukemia
Issue Information
The thrombopoietin receptor S264F mutant drives MPN with marrow fibrosis through a dual mechanism
Chemoimmunotherapy‐associated CD20 ( MS4A1 ) resistance mutations in Waldenström macroglobulinemia: Epitope disruption independent of expression with implications for CD20‐directed cellular therapies
Integrating Gaucher disease (GD) into mainstream hematological curriculum training
SLV‐404, an anti‐RYK antibody–drug conjugate, is effective in Richter transformation patient‐derived xenografts
Generic versus branded imatinib in frontline chronic myeloid leukemia: A systematic review and meta‐analysis
One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T‐cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized‐controlled trial
Longitudinal assessments of MRD in high‐risk newly diagnosed transplant‐ineligible multiple myeloma in the BENEFIT study (IFM2020‐05)
Integrating paroxysmal nocturnal hemoglobinuria (PNH) into mainstream hematological curriculum training
Quality of life with nivolumab and AVD first‐line treatment of Hodgkin lymphoma in the Phase II GHSG NIVAHL trial
Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma
Human erythroid models of sickle cell disease
The maturation of precision medicine into pragmatic, patient‐centered care: A commentary on the 2026 EHA CLL Guidelines
Response to two comments on “EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation” by S. Molica and A. Tedeschi: Beyond the binary choice
Comment on “EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation”
Long‐term mutational analysis, clonal metrics, and dynamics in patients with chronic idiopathic neutropenia
A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist
EUVIMED